Dr. Bruce N. Ames, Ph.D. is a renowned scientist with a distinguished academic background, and a Juvenon co-founder. He is a Professor of Biochemistry and Molecular Biology at the University of California, Berkeley. Dr. Ames is also Senior Scientist, Children’s Hospital of Oakland Research Institute. He is a member of the National Academy of Sciences and he was on their Commission on Life Sciences. He was a member of the board of directors of the National Cancer Institute, the National Cancer Advisory Board, from 1976 to 1982. Dr. Ames was the recipient of a leading award for cancer research, the General Motors Cancer Research Foundation Prize (1983), a leading award in environmental achievement, the Tyler Prize (1985), the Gold Medal Award of the American Institute of Chemists (1991), the Glenn Foundation Award of the Gerontological Society of America (1992), and the Lovelace Institutes Award for Excellence in Environmental Health Research (1995), the Achievement in Excellence Award of the Center for Excellence in Education (1996), the Honda Prize of the Honda Foundation, Japan (1996), the Japan Prize, (1997), and the Kehoe Award, American College of Occupational and Environmental Med. (1997), the Medal of the City of Paris (1998), the Joseph Priestley Award (1998), and the U.S. National Medal of Science (1998). His over 540+ publications have resulted in his being among the few hundred most-cited scientists in all fields: 23rd most cited (1973-1984).
Professor Ames has been the international leader in the field of mutagenesis and genetic toxicology for over 40 years. His work has had a major impact on, and changed the direction of, basic and applied research on mutation, cancer, and aging. The development of the Ames mutagenicity test as a practical tool for the detection of potential carcinogens has led to its use in over 3000 laboratories and in all of the major drug and chemical companies, where it has had a major influence in weeding out mutagenic chemicals while it is cheap to do so and before they are introduced into commerce. The current research of Dr. Ames’ on cells focuses on the oxidative damage to DNA and its relationship to mutagenesis, carcinogenesis and the degenerative diseases of aging. His main interest is in the prevention of cancer and other degenerative diseases of aging.
Dr. Tory Hagen, Ph.D. is a co-inventor with Dr. Ames on the patent that Juvenon licensed from the University of California, Berkeley, and co-author with Dr. Ames of Mitochondrial Decay in Aging and its Consequences to the Cell. Dr. Hagen is a Professor, Department of Biochemistry and Biophysics and Principal Investigator and Jamieson Endowed Chair in Healthspan Research at the Linus Pauling Institute at Oregon State University, Corvallis, OR. Previously Dr. Hagen was a Postdoctoral Fellow and Assistant Specialist Research Scientist in the Department of Molecular and Cell Biology at the University of California, Berkeley. He earned his Ph.D. in biochemistry at Emory University.
Nathan D. Hamilton is Juvenon’s Chief Executive Officer and a founder of the business. Mr. Hamilton has been an executive with a number of consumer, biotechnology, medical diagnostic and medical device companies. Mr. Hamilton received his B.A. in Physics from the University of California, Berkeley and his Masters of Business Administration from Harvard University Graduate School of Business.
Michael P. McManus is Juvenon’s Chief Financial Officer. During his career, Mr. McManus has been a chief financial officer and a strategic advisor for publicly traded companies. He previously served as CFO at Aeolus Pharmaceuticals, Inc. and as controller and principal accounting officer at Spectrum Pharmaceuticals, Inc. Mr. McManus began his career at PricewaterhouseCoopers LLP as an audit manager for healthcare and financial services companies. Mr. McManus is a retired Certified Public Accountant and has a Bachelor of Science degree in Accounting from the University of Southern California.